| Project/Area Number |
16591282
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
FUJII Teruhiko Kurume University, Medical School, Associate Professor, 医学部, 助教授 (50199288)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOKOYAMA Goro Kurume University, Medical School, Research Associate, 医学部, 助手 (00309808)
YAMAGUCHI Miki Kurume University, Medical School, Research Associate, 医学部, 助手 (70330834)
KUWANO Michihiko Kurume University, Medical School, Professor, 医学部, 教授 (80037431)
|
|---|
| Project Period (FY) |
2004 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2006: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2005: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2004: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Keywords | breast cancer / YB-1 / Cap43 / ER-α / Akt / HER2 / NDRG1 / ER / 薬剤耐性 |
|---|
| Research Abstract |
1. Expression of nuclear YB-1 thus may play an essential role in acquirement of malignant characteristics through HER2-Akt dependent pathways in breast cancer patients. Nuclear YB-1 localization would thus be expected to be molecular target of intrinsic importance not only for acquirement of multidrug resistance but also for tumor growth dependent upon HER2 and estrogen receptor.
2. Estradiol-induced down-regulation of Cap43 gene thus appeared to be mediated through ER-α dependent pathway in breast cancer cells in culture and in patients. Cap43 will be a molecular marker useful for determination of the therapeutic efficacy of anti-estrogenic anticancer agents in breast cancer.
|
